Purpose: To retrospectively analyze and estimate the dosimetric benefit of online and offline motion mitigation strategies for prostate IMRT.
the field order approach showed less sensitive response regarding motion and reduced interpatient variation. has been mitigated with optimized margins [1] [2] [3] or endorectal balloons. 4 In the last decades, online motion detection including MV portal imaging, 5, 6 cone beam computed tomography (CT), 7 ultrasound, 8, 9 electromagnetic transponders, [10] [11] [12] and magnetic resonance imaging 13, 14 have been introduced.
On the one side, the resulting motion information facilitated the development of real-time mitigation techniques using a couch, [15] [16] [17] multileaf-collimator (MLC)-tracking, 18, 19 or gated delivery. 20, 21 On the other side, it is possible to reconstruct the delivered dose, that is, a four-dimensional (4D) dose distribution, based on the actually observed motion during the treatment. [22] [23] [24] Although motion of the prostate during radiotherapy has been detected 25, 26 and adaptive strategies have been applied for prostate patients, 2,15,27 a comprehensive comparison of motion management strategies is still pending. 28 Here, we present a coherent analysis of the correlation between intra-fractional prostate motion and dosimetric changes induced by the motion considering both target coverage and organ at risk (OAR) sparing metrics. Real-time motion data 29, 30 stemming from 21 patients were used, and different motion mitigation approaches were compared. Our study provides valuable guidance to implement clinical decision support regarding the adequate motion mitigation strategy for prostate IMRT patients. Furthermore, we introduce two innovations: (a) a novel motion metric which quantifies the target motion relative to the actual delivered beam (DistToBeam) and (b) the strategy of changing the field order (AngHV) that can be applied for many clinical scenarios in IMRT.
| MATERIALS AND METHODS

2.A | Patient data
Data for 21 prostate patients who received step-and-shoot IMRT with a Siemens Artiste treatment device equipped with a 160-leaf MLC (Siemens AG, Munich, Germany) in 35 fractions at our institution was acquired. Informed consent was obtained from all included individual participants. The study was approved by the ethics committee of the medical faculty at our university. The prostate was defined as an integrated boost volume and the treatment plan was optimized with the goal of a prescribed median dose of 76 Gy with an enclosing isodose of at least 95% (72.2 Gy). The prostate was expanded by a margin of 7 mm including the base of the seminal vesicles to construct the planning target volume (PTV) with a prescribed dose of 70 Gy with an enclosing isodose of at least 95% (66.5 Gy). Treatment planning was performed with our in-house clinical treatment planning systems VOXELPLAN and KonRad which facilitate a singular value-decomposed pencil beam algorithm. 31 The immanent inaccuracies of pencil beam algorithms compared with more sophisticated approaches in heterogeneous media were assumed negligible for prostate treatments. 32 Nine coplanar equiangular fields with a 6-MV photon beam with a flattening filter were used (Gantry angles at 200°, 240°, 280°, 320°, 0°, 40°, 80°, 120°, 160°in a clockwise order according to the IEC 61217 standard). The patient was positioned in head-first supine position using a head rest, a knee rest, and a foot rest. There was no dietary protocol, but the patients were asked for having an empty rectum and a full bladder during the planning CT and treatment fractions. For each patient, the clinically applied treatment plan was used as a reference to simulate different motion mitigation strategies. The average number of MLC segments per plan was 81, and the total number of fractions was 734 in our cohort.
2.B | Motion metrics
Target motion was monitored with the Calypso 4D localization sys- To extract intrafractional motion for this study, the initial displacement has been set to zero with an offset correction based on The actual treatment was delivered without intrafractional motion adaption (NoCorr). Based on the time correlated beam delivery information, the observed target motion was sampled per delivered beam segment and used for the reconstruction of the dose distribution that was actually delivered during the treatment.
2.D.2 | Repositioning scenario
Real-time adaptation scenarios with a couch-shift technique have been simulated with repositioning thresholds of 3, 5, and 7 mm (Rep3, Rep5, and Rep7, respectively) by using the sampled target motion of the patients. In this scenario, the repositioning has been applied if the sampled displacement exceeds the threshold at any orthogonal direction. Therefore, the displacement of all components is immediately set to zero simulating infinitely fast patient repositioning. After repositioning, the sampled motion continues relative to the applied centering. Since the duration of repositioning in this simulation is neglected, the beam delivery timing and ending of the sampled motion coincides with the NoCorr case.
2.D.3 | Field order modification scenario
For this offline motion management scenario, we simulate a treatment that starts with horizontal fields and finishes with vertical fields 
2.E | Correlation analysis
The Pearson product-moment correlation coefficient (CC) between the dose metric (DD95 or DV65) and the motion metric (LR, PA, and SI, DistToOrigin, DistToBeam) was computed for every patient individually. The number of data points underlying the CC calculation was up to 35 (number of fractions). Subsequently, the mean values of all 21 patients were extracted. The mean value of the CC in the NoCorr scenario was used to identify the motion metric with the best correlation to the dosimetric endpoints.
Linear regression was performed to quantify the sensitivity of all dose metrics with a slope (i.e., dose metric per motion metric) in %/ mm. A motion management strategy with low motion sensitivity would result in less dose changes from the static case for a given motion (i.e., a smaller slope). Consequently, the strategy can be considered more robust against motion. The standard deviation of the slope in patient statistics was included as error estimate.
| RESULTS
3.A | Motion metric
Mean, standard deviation (SD), minimum and maximum of the sampled target displacements are listed in Table 1 
3.B | Dose quality metric
The changes in the dose metrics calculated for all scenarios are listed in Table 2 for both the fractional dose and the cumulative dose per patient. For the fractional dose in NoCorr, the change of dose metric DD95 for PTV and prostate was À2.0 AE 3.5% and À0.9 AE 2.1 % ranging from À24.9 to 2.2% and À26.7 to 1.8%, respectively. The negative sign indicates less dose in NoCorr than for the static case.
For both the PTV and the prostate, the minimum values showed large deviation from the static case. For Rep7, 5, and 3, the dose deviation decreases as the threshold decreases. DD95 of AngHV shows improvement of the minimum value compared with AngCW from À16.9% to À10.1% for the prostate, while it stays comparable for the PTV with about À24%. For the cumulative dose, the PTV DD95 and the prostate DD95 were within 5% for all patients in all scenarios.
Bladder V65 increased for all motion and correction scenarios in comparison to the static case, while the rectum V65 showed an overall decrease. Both is valid for fractional and cumulative doses;
see Table 2 . This may be explained by a general drift of the entire anatomy toward the posterior direction. For the fractional doses, T 
3.C | Correlation coefficients
Mean values of the patient-wise CCs are listed in Table 3 . The PTV shows a more clear correlation than for the total data set averaged over all patients (compare Fig. 1 ).
3.D | Regression slopes
The patient-wise analysis of regression slope is shown in Table 4 for all dose metrics in combination with the motion metric that showed the highest correlation. Both free motion scenarios, NoCorr and AngCW, showed comparable results due to the similarity of the delivery method (i.e., clockwise deliveries without adaptation). Consequently, the slope values of repositioning and AngHV scenarios can be easily compared to a common reference. 
3.E | PTV
3.G | Bladder
The CC of the bladder DV65 showed the strongest correlation with the SI component with a positive sign. It implies that the target displacement toward inferior (superior) introduces a very linear increase (reduction) of DV65 in this study. For this selected combination, mean and SD of the slope in all repositioning scenarios have no significant change compared with the NoCorr case. On the other hand, the AngHV showed reduction in both mean and SD.
3.H | Rectum
For the rectum DV65, the motion metric PA showed the highest correlation among all motion metrics. The target displacement toward anterior (posterior) increases (decreases) the rectum DV65 in this study. As it was found in the bladder, the slope values of the rectum did not exhibit a significant change for all scenarios except for AngHV that showed a shallower slope of 8.1 AE 4.6 %/mm.
As it was demonstrated in Figs. 1 and 2 for the prostate, the patient-specific curves of OARs also introduce variation in the cohort data. AngHV showed smaller variation as measured by the SD of the slope compared with the other scenarios. At the same time, the mean value of the slopes was found to be smaller indicating a reduction in motion sensitivity by AngHV for V65 in both the bladder and the rectum.
| DISCUSSION
Our patient-wise analysis revealed a clear linear correlation between dose and motion metrics. The motion metric of DistToBeam showed the highest correlation in the correlation analysis for both PTV and prostate for all considered motion mitigation strategies rather than DistToOrigin, as target motion along the beam axis does not affect the target dose significantly. For OARs, the strongest correlation was found in SI and PA direction for bladder and rectum, respectively.
In agreement with a previous study, 24 the motion metric of mean displacement showed a stronger correlation for the PTV than for the prostate, as it has to be expected. While Langen et al. found a poor correlation with correlation coefficient of À0.26 between mean displacement and CTV coverage, we observed stronger correlation (À0.63) for the corresponding metric, DistToOrigin. This observation equally applies to prostate coverage. The differences can be explained by different margin designs with an integrated boost concept in our study, which directly leads to changes in the prostate coverage in case of target motion due to the directly surrounding dose fall off. Moreover, we established the correlation model using an additional motion metric, that is, DistToBeam, which accounts for 
Correlation plots between a dose metric and a motion metric for NoCorr (top), repositioning cases (2nd, 3rd, and 4th rows), and AngHV scenario (bottom). The dose metrics correspond to DD95 for the prostate (left) and DV65 for the bladder (right). The motion metric corresponds to the mean of DistToBeam for the prostate and SI for the bladder per fraction. The linear regression curves are shown with solid lines; the corresponding correlation coefficients (CC) and slopes are given for each subplot.
the beam geometry in combination with a patient-wise specific analysis to extract clear correlations.
The scenarios without adaptation, NoCorr and AngCW, showed similar motion sensitivity as measured by the regression slopes, even though the sampled motion amplitudes and timings were different.
The real-time adaptation scenarios with repositioning, Rep3, Rep5, and Rep7, showed a gradual change in the sensitivity as
Rep3 is the most motion insensitive among them. In this study, the Rep7 showed minor improvement in dose, see Table 2 , and the motion sensitivity in mean and SD was similar to the free motion cases.
Correlation plot between the prostate DD95 and the motion metric DistToBeam, plotted for each patient. The linear regression curves of patient-wise analysis is shown with a solid line; the corresponding correlation coefficients (CC) and slopes are given for each subplot.
The offline strategy, AngHV, reduced the motion sensitivity to the level of Rep3 for both PTV and prostate. As shown in Table 2 , the dose quality for the AngHV was comparable to the Rep3 or Rep5 for PTV and prostate. The AngHV strategy improved dose and reduced motion sensitivity without any additional equipment or treatment interruption. Furthermore, it avoids dose degradation due to motion below the threshold inherent in the repositioning scenario.
For OARs, AngHV showed reduction in sensitivity in both mean and SD; on the other hand, the repositioning scenarios did not show significant change on the sensitivity. The beam re-arrangement will cost time, which seems to contraindicate the aims of this approach based on the assumption of larger motion with longer treatment times.
Our dose recalculations were made without considering this elongation because of the absence of this information. This decision can be justified by the following arguments: Assuming a gantry speed of 360°/min, the re-arrangement will lead to an additional fraction time of approximately 2.5 min to our 10 min for the clockwise order. Based on our own data analysis using 25 prostate patients including the 21 patients here, this may lead to an increase in mean longitudinal and vertical displacement of approximately 0.3 mm. This assumption is based on an extrapolation of the mean displacement of À0.1 mm per minute as observed in the first 9 min within our patient cohort. As the prostate motion tends to be saturated after 9 min, 35 this may be considered a conservative estimate.
The motion in SI direction was not mitigated in the AngHV approach. That needs to be investigated in further studies possibly applying noncoplanar optimized beams. 36 The extracted correlations are based on the assumption of rigid patient motion. We understand the possibility of shape changes during the treatment; however, the tracked motion data in this study does not provide information in this regard. Consequently, the estimation of the dosimetric impact was performed under the assumption of a stable anatomy. For the OARs, where we report dosimetric quality indicators that are related to the high-dose volume, the assumption of a rigid anatomy is particularly relevant for the "prostate side" which is irradiated at higher dose. Potential shape changes far away from the prostate (e.g., due to varying organ filling) have a smaller effect on the reported metrics. More detailed morphological sampling of organ motion, shape change, and combination of the strategies can be investigated in further studies.
In this study, the dosimetric changes on rectum were most beneficial in the free motion scenario ( Table 2 ). The motion adaptation strategies reduced deviations from the planned dose which was higher than in the free motion case (NoCorr). This means, on average, all investigated adaptation techniques increased the dose in the rectum compared with the free motion scenario. This can be explained by the prostate drift toward the posterior direction in the free motion case which moves the rectum into a lower dose region, too.
This study was restricted to step and shoot (SNS) IMRT. The applicability of the field order modification is not straightforward for 
